Equillium Inc
NASDAQ:EQ
Equillium Inc
Depreciation & Amortization
Equillium Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Equillium Inc
NASDAQ:EQ
|
Depreciation & Amortization
$138k
|
CAGR 3-Years
25%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
33%
|
CAGR 10-Years
27%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
$5.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
20%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$207.2m
|
CAGR 3-Years
18%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$482.9m
|
CAGR 3-Years
19%
|
CAGR 5-Years
18%
|
CAGR 10-Years
25%
|
|
Equillium Inc
Glance View
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.
See Also
What is Equillium Inc's Depreciation & Amortization?
Depreciation & Amortization
138k
USD
Based on the financial report for Sep 30, 2024, Equillium Inc's Depreciation & Amortization amounts to 138k USD.
What is Equillium Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
36%
Over the last year, the Depreciation & Amortization growth was 15%. The average annual Depreciation & Amortization growth rates for Equillium Inc have been 25% over the past three years , 36% over the past five years .
You don't have any saved screeners yet